Clinical Trials | March 12, 2024
Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
Women emerge as the cornerstone of this monumental undertaking
These approvals mark significant progress for Venus Remedies in expanding its market presence
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
ANVISA issues CGMP to Concord Biotech’s Unit I
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Subscribe To Our Newsletter & Stay Updated
